Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 44, Issue SUPPL., 2002, Pages 31-41

  Alberola, Vicente ^a   Cortesi, Enrico ^b   Juan, Oscar ^a  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemoradiotherapy; Combination chemotherapy; Non small cell lung cancer; Weekly paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE CALCULATION; DRUG RESPONSE; DYSPNEA; ESOPHAGITIS; FATIGUE; HUMAN; HYPERSENSITIVITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; METASTASIS; MOTOR NEUROPATHY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PREMEDICATION; RADIOSENSITIZATION; RASH; REVIEW; SENSORY NEUROPATHY; STOMATITIS; VOMITING;

EID: 12244260733     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1040-8428(02)00104-x     Document Type: Review

References (41)

1. Ginsberg R.J., Vokes E.E., Raben A. Non-small cell lung cancer. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: principles and practice of oncology. 4th ed. 1997;858-910 Lippincott-Raven, Philadelphia, PA.
2. Frasci G., Panza N., Comella P., et al. Cisplatin, gemcitabine and paclitaxel in locally advanced or metastatic non-small cell lung cancer: a phase I-II study. J. Clin. Oncol. 17:1999;2316-2325.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 311:1995;899-909.
4. Murphy W.K., Fossella F.V., Winn R.J., et al. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J. Natl. Cancer Inst. 85:1993;384-388.
5. Chang A.V., Kim K., Click J., et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Oncology Cooperative Group results. J. Natl. Cancer Inst. 85:1993;388-394.
6. Akerley W. Recent developments in weekly paclitaxel therapy in lung cancer. Curr. Oncol. Rep. 3:2001;165-169.
7. Seidman A.D., Hudis C.A., Albanel J., et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 16:1998;3353-3361.
8. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24:(Suppl. 10):1997;S10.3-S10.10.
9. Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
10. Milross C.G., Mason K.A., Hunter N.R., et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J. Natl. Cancer Inst. 88:1996;1308-1314.
11. Akerley W., Glantz M., Choy H. Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin. Oncol. 23:(Suppl. 12):1996;14-18.
12. Akerley W., Herndon J., Egorin M., et al. CALGB 9731: phase II trial of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;A1783.
13. Akerley W. Paclitaxel in advanced non-small cell lung cancer: an alternative high-dose weekly schedule. Chest. 117:(Suppl. 1):2000;152-155.
14. Chang A.Y., Rubins J., Asbury R., Boros L., Hui L.F. Weekly paclitaxel in advanced non-small cell lung cancer. Semin. Oncol. 28:(Suppl. 14):2001;10-13.
15. Alberola V., Vidal O., Ordoño F., et al. Low-dose weekly paclitaxel (WP) in the treatment of unresectable or metastatic non-small cell lung cancer (NSCLC). Neurological and electrophysiological evaluation of neurotoxicity. Proc. Am. Soc. Clin. Oncol. 20:2001;2837. abstract.
16. Fidias P., Supko J.G., Martins R., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin. Cancer Res. 7:2001;3942-3949.
17. Koumakis G., Demeri M., Barbounis V., et al. Is weekly paclitaxel superior to paclitaxel given every three weeks? Results of a phase II trial. Lung Cancer. 35:2002;315-317.
18. Feliu J., Martín G., Lizón J., et al. Sequential therapy in advanced non-small cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study. Ann. Oncol. 12:2001;1369-1374.
19. Ramanath R.K., Capozzoli M.J., Trump D.L., Jacobs S., Belani C.P. Escalating doses of weekly paclitaxel in combination with carboplatin: a phase I study in advanced malignancies. Proc. Am. Soc. Clin. Oncol. 18:1999;A638.
20. Belani C.P. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin. Oncol. 28:(Suppl. 14):2001;14-16.
21. Cohen R.B., Mueller S.C., Haden K., de Souza P. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Cancer Invest. 18:2000;422-428.
22. Frasci G., Panza N., Comella P., et al. Cisplatin, gemcitabine and paclitaxel in locally advanced or metastatic non-small cell lung cancer: a phase I-II study. J. Clin. Oncol. 17:1999;2316-2325.
23. Morales S., Balil A., Salud A., et al. Paclitaxel (P), gemcitabine (G) and cisplatin (C) in non-resectable non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;550a. abstract 2167B.
24. Paz-Ares L., Sanchez-Rivera P., Gomez-Martin R., et al. A phase II trial of the triplet paclitaxel, cisplatin and gemcitabine (Tcg) in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 2000;19. abstract 2155.
25. Lokich J.J., Anderson N., Bern M., Coco F., Dow E. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen. A phase I-II of paclitaxel, cisplatin and vinorelbine. Cancer. 85:1999;499-503.
26. © followed by maintenance P vs observation for patients (pts) with advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 323a:2001;A1287.
27. Murren J.R., Peccerillo K., DiStasio S.A., et al. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemother. Pharmacol. 46:2000;43-50.
28. Sorensen J.B., Stenbygaard L.E., Dombernowsky P., Hansen H.H. Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small cell lung cancer. Ann. Oncol. 10:1999;1043-1049.
29. Isla D., Rosell R., Sanchez J.J., et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 19:2001;1071-1077.
30. Choy H., Akerley W., Safran H., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 16:1998;3316.
31. Choy H., Akerley W., DeVore R.F. Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer. Semin. Oncol. 26:(Suppl. 2):1999;36-43.
32. Lau D., Leigh B., Gandara D., et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer consortium phase II trial. J. Clin. Oncol. 19:2001;442-447.
33. Alvarez A., Mickiewicz E., Pris N., et al. Weekly Taxol high dose intensity (DI) treatment, phase II study. Proc. Am. Soc. Clin. Oncol. 15:1996;183. abstract 383.
34. Curran W.J., Scott C., Bonomi P., et al. Initial report of locally advanced multimodality protocol (LAMP): ACR 427: a randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 12:2001;20. abstract 1244.
35. Alberola V., Rosell R., González-Larriba J.L., et al. Single agent Taxol 3-hour infusión in untreated advanced non-small cell lung cancer. Ann. Oncol. 6:(Suppl. 3):1995;49-52.
36. Hainsworth J.D., Thompson F.D., Greco F.A., et al. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J. Clin. Oncol. 13:1995;1609-1614.
37. Calderoni A., Cerny T. Taxanes in lung cancer: a review with focus on the European experience. Crit. Rev. Oncol. Hematol. 38:2001;105-127.
38. Milward M.J., Bishop J.F., Friedlander M., et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. J. Clin. Oncol. 14:1996;142-148.
39. Ranson M., Davidson N., Nicolson M., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J. Natl. Cancer Inst. 92:2000;1074-1080.
40. Lopes N.M., Adams E.F., Pitts T.W., et al. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 32:1993;235-242.
41. Barduagni M.A., Fabi M., De Marinis F., et al. Carboplatin (C) and weekly paclitaxel (P): a phase I-II study in advanced NSCLC. Proc. Am. Soc. Clin. Oncol. 1999;18. abstract 496a.